Imugene Overview
- Year Founded
-
1986
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
IMU
- Investments
-
4
- Share Price
-
$0.03
- (As of Friday Closing)
Imugene General Information
Description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact Information
Website
www.imugene.comCorporate Office
- 4-6 Bligh Street
- Suite 12.01, Level 12
- Sydney, New South Wales 2000
- Australia
Corporate Office
- 4-6 Bligh Street
- Suite 12.01, Level 12
- Sydney, New South Wales 2000
- Australia
Imugene Timeline
Imugene Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.03 | $0.03 | $0.02 - $0.10 | $250M | 7.57B | 19.9M | -$0.01 |
Imugene Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
|---|---|---|---|---|
| EV | 188,616 | 188,616 | 285,707 | 658,062 |
| EBITDA | (98,582) | (98,582) | (26,607) | (27,347) |
| Net Income | (98,091) | (98,091) | (25,489) | (27,442) |
| Total Assets | 101,194 | 101,194 | 130,442 | 101,539 |
| Total Debt | 0 | 0 | 366 | 463 |
Imugene Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Imugene Comparisons
Industry
Financing
Details
Imugene Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Amphivena Therapeutics | Venture Capital-Backed | South San Francisco, CA |
Imugene Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Imugene Patents
Imugene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2018904373-A0 | Methods of treating proliferative disorders | Inactive | 16-Nov-2018 | ||
| AU-2018903968-A0 | A vaccine composition and uses thereof | Inactive | 19-Oct-2018 | ||
| AU-2018903558-A0 | A vaccine composition and uses thereof | Inactive | 21-Sep-2018 | ||
| AU-2018903518-A0 | A vaccine composition and uses thereof | Inactive | 19-Sep-2018 | ||
| AU-2018900368-A0 | A vaccine composition and uses thereof | Inactive | 07-Feb-2018 |
Imugene Executive Team (13)
| Name | Title | Board Seat |
|---|---|---|
| Leslie Chong | Chief Executive Officer, Managing Director & Board Member | |
| Ursula McCurry | Chief Clinical Operations Officer | |
| Nick Ede | Head, Corporate Development | |
| Giovanni Selvaggi MD | Chief Medical Officer | |
| Paul Woodard MD | Chief Medical Officer |
Imugene Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Self | Board Member | ||
| Self | Board Member | ||
| Self | Board Member | ||
| Imugene | Chief Executive Officer, Managing Director & Board Member | ||
| Self | Founder & Executive Chairman |
Imugene Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Imugene Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vaxinia | 18-Nov-2019 | Biotechnology | |||
| City of Hope (CF33 oncolytic virus) | 15-Jul-2019 | Buildings and Property | |||
| Biolife Science | 23-Oct-2013 | Pharmaceuticals | |||
| Lingual Consegna | 31-Jul-2012 | Merger/Acquisition | Drug Delivery |
Imugene Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Imugene (Cell Therapy Manufacturing Facility in North Carolina) | Buildings and Property | NC |
Imugene ESG
Risk Overview
Risk Rating
Updated August, 29, 2023
30.72 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Biotechnology
Subindustry
of 404
Rank
Percentile
Imugene FAQs
-
When was Imugene founded?
Imugene was founded in 1986.
-
Who is the founder of Imugene?
Paul Hopper is the founder of Imugene.
-
Who is the CEO of Imugene?
Leslie Chong is the CEO of Imugene.
-
Where is Imugene headquartered?
Imugene is headquartered in Sydney, Australia.
-
What is the size of Imugene?
Imugene has 5 total employees.
-
What industry is Imugene in?
Imugene’s primary industry is Drug Discovery.
-
Is Imugene a private or public company?
Imugene is a Public company.
-
What is Imugene’s stock symbol?
The ticker symbol for Imugene is IMU.
-
What is the current stock price of Imugene?
As of 11-Oct-2024 the stock price of Imugene is $0.03.
-
What is the current market cap of Imugene?
The current market capitalization of Imugene is $250M.
-
Who are Imugene’s competitors?
NexImmune and Amphivena Therapeutics are competitors of Imugene.
-
What is Imugene’s annual earnings per share (EPS)?
Imugene’s EPS for 12 months was -$0.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
